2010
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2007
Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data